MS Disease and Providing a Biologic Perspective and Reducing the Symptoms of the Disease with the Help of Stem Cells

Ehsan Sharifipour, Hoorolnesa Ameli, Shima Sadat Hashemi Madani

Abstract


Introduction: MS is one of the most common inflammatory diseases of the central nervous system, with the destruction of nerves. One of the symptoms of MS disorder is dystonia, fatigue, spasticity, disturbances, lack of sensation in the organs, cognitive impairment, weakness, tremor, pain, bladder and bowel dysfunction. Method: The search was carried out in the Pubmed/Medline database. 63 The study was designed to investigate patients with MS and therapeutic samples that were materially similar to the current research, and are included in this article. Findings: Therapeutic injection methods in MS have responded, but patients are still in trouble. Studies have shown that the use of stem cells for treating patients with MS has been fruitful and can be used to treat MS. Discussion: As it has been said, the most important treatment challenges in this way is to reduce treatment, and moreover, that anti-MS drugs in advanced forms are limited. Hence, the production of new, improved medicines for the complete treatment of MS is essential. Stem cells play a veryw important role in the repair process, and the complications of these cells are low in patients and provide an acceptable response. Reliably, the focus on new immunology methods with more biological properties has a greater impact on the treatment category. They will have patients.

Keywords


MS, Balance, Immunology, Therapeutic Proposal

Full Text:

PDF

References


-Gafson, A.; Giovannoni, G.; Hawkes, C.H. The diagnostic criteria for multiple sclerosis: From charcot to mcdonald. Mult. Scler. Relat. Disord. 2012, 1, 9–14.

-Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. Journal of Neurology. 2009; 256(11):1891–8.

-Olek MJ. Epidemiology, risk factors, and clinical features of multiple sclerosis. Waltham: Up To Date; 2004.

-Grytten, N.; Torkildsen, O.; Myhr, K.M. Time trends in the incidence and prevalence of multiple sclerosis in norway during eight decades. Acta Neurol. Scand. 2015, 132, 29–36.

- Compston, A.; Coles, A. Multiple sclerosis. Lancet 2002, 359, 1221–1231.

-Halper J. The evolution of nursing care in multiple sclerosis. International Journal of MS Care. 2000; 2(1):14–22.

-Seyedfatemi N, Heydari M, Hoseini AF. Self esteem and its associated factors in patients with multiple sclerosis. Iran Journal of Nursing. 2012; 25(78):14-22.

-Engel RA, DeLuca J, Gaudino EA, Diamond BJ, Christodoulou C. Acquisition and storage deficits in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology (Neuropsychology, Development and Cognition: Section A). 1998; 20(3):376–90.

-Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Archives of Neurology. 1990; 47(1):94–7.

-Fasoli SE, Trombly CA, Tickle Degnen L, Verfaellie MH. Effect of instructions on functional reach in persons with and without cerebrovascular accident. American Journal of Occupational Therapy. 2002; 56(4):380–90.

-Katsara, M.; Matsoukas, J.; Deraos, G.; Apostolopoulos, V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim. Biophys. Sin. 2008, 40, 636–642. [CrossRef] [PubMed]

Lublin, F.D.; Reingold, S.C. Defining the clinical course of multiple sclerosis: Results of an international Bsurvey. Neurology 1996, 46, 907–911. [CrossRef] [PubMed]

Eckstein, C.; Bhatti, M.T. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. Surv. Ophthalmol. 2016, 61, 318–332.

- Mahad, D.H.; Trapp, B.D.; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015, 14, 183–193. [CrossRef].

Minagar, A.; Alexander, J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9, 540–549.[CrossRef] [PubMed].

-Poursadoughi A, Dadkhah A, Pourmohamadreza-Tajrishi M, Biglarian A. Psycho-Rehabilitation Method (Dohsa-Hou) and Quality of Life in Children with Cerebral Palsy . Iranian Rehabilitation Journal. 2015; 13(2):28-33

Steinman, L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299–302. [CrossRef]

Bennett, J.; Basivireddy, J.; Kollar, A.; Biron, K.E.; Reickmann, P.; Jefferies, W.A.; McQuaid, S. Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model eae. J. Neuroimmunol. 2010, 229, 180–191. [CrossRef] [PubMed]

- Katsara, M.; Matsoukas, J.; Deraos, G.; Apostolopoulos, V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim. Biophys. Sin. 2008, 40, 636–642.

-Farjam, M.; Zhang, G.X.; Ciric, B.; Rostami, A. Emerging immunopharmacological targets in multiple sclerosis. J. Neurol. Sci. 2015, 358, 22–30. [CrossRef] [PubMed].

- Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23, 683–747.[CrossRef] [PubMed].

-Hemmer, B.; Nessler, S.; Zhou, D.; Kieseier, B.; Hartung, H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2, 201–211. [CrossRef] [PubMed]

-Jiang, J.; Kelly, K.A. Phenotype and function of regulatory t cells in the genital tract. Curr. Trends Immunol. 2011, 12, 89–94. [PubMed]

-Bianchini, E.; De Biasi, S.; Simone, A.M.; Ferraro, D.; Sola, P.; Cossarizza, A.; Pinti, M. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunol. Lett. 2017, 183, 1–7. [CrossRef] [PubMed]

-Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23, 683–747.[CrossRef] [PubMed]

-Dandekar, A.A.; Wu, G.F.; Pewe, L.; Perlman, S. Axonal damage is t cell mediated and occurs concomitantlywith demyelination in mice infected with a neurotropic coronavirus. J. Virol. 2001, 75, 6115–6120. [CrossRef] [PubMed]

-Münzel, E.J.; Williams, A. Promoting remyelination in multiple sclerosis-recent advances. Drugs 2013, 73, 2017–2029. [CrossRef] [PubMed]

-Inglese, M.; Petracca, M. Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia. Schizophr. Res. 2015, 161, 94–101. [CrossRef] [PubMed]

- Koriem, K.M.M. Multiple sclerosis: New insights and trends. Asian Pac. J. Trop. Biomed. 2016, 6, 429–440.[CrossRef]

- Dolati, S.; Babaloo, Z.; Jadidi-Niaragh, F.; Ayromlou, H.; Sadreddini, S.; Yousefi, M. Multiple sclerosis:Therapeutic applications of advancing drug delivery systems. Biomed. Pharmacother. 2017, 86, 343–353.[CrossRef] [PubMed]

-Kallaur, A.P.; Lopes, J.; Oliveira, S.R.; Simão, A.N.; Reiche, E.M.; de Almeida, E.R.D.; Morimoto, H.K.; de Pereira, W.L.; Alfieri, D.F.; Borelli, S.D.; et al. Immune-inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: Increased peripheral inflammation but less acute neuroinflammation. Mol. Neurobiol. 2016, 53, 5191–5202. [CrossRef] [PubMed]

Mirshafiey, A.; Jadidi-Niaragh, F. Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol. Immunotoxicol. 2010, 32, 543–554. [CrossRef] [PubMed]

-BLANPAIN, C., LOWRY, W. E., GEOGHEGAN, A., POLAK, L. & FUCHS, E. 2004. Self-Renewal, Multipotency, and the Existence of Two Cell Populations within an Epithelial Stem Cell Niche. Cell, 118, 635-648.

-FRIEDENSTEIN, A. J., CHAILAKHJAN, R. K. & LALYKINA, K. S. 1970. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Proliferation, 3, 393-403.

-MEIRELLES, L. D. S., CHAGASTELLES, P. C. & NARDI, N. B. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science, 119, 2204-2213.

-BUNNELL, B. A., FLAAT, M., GAGLIARDI, C., PATEL, B. & RIPOLL, C. 2008. Adipose-derived Stem Cells: Isolation, Expansion and Differentiation. Methods (San Diego, Calif.), 45, 115-120.

-ABDALLAH, B. M. & KASSEM, M. 2007. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Therapy, 15, 109-116.

-CAPLAN, A. I. 1991. Mesenchymal stem cells. Journal of Orthopaedic Research, 9, 641-650.

-MURAGLIA, A., CANCEDDA, R. & QUARTO, R. 2000. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. Journal of Cell Science, 113, 1161-1166.

-Wolff E, Gao X, Yao K, Andrews Z, Du H,Elsworth J and Taylor HEndometrialstem cell transplantation restores dopamineproduction in a Parkinson disease model. JCell Mol Med.2010;15:747–55.

-Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J. Endometrial regenerative cells: a novel stem cell population. J Transl Med.2007;5:57.

-Da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008 Sep;26(9):2287-99.

- Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008 Feb;14(2):181-7.

-Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004 Dec;14(6):1035-41

-Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B, Galipeau J. Mesenchymal stromal cellderived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008 Dec 15;112(13):4991-8.

-Bai, L.; Lennon, D.P.; Maier, K.; Caplan, A.L.; Miller, S.D.; Miller, R.H. Human bone marrow-derived mesenchymal stem cells induce Th2 polarized immune response and promote endogenous repair in animalmodels of multiple sclerosis. Glia 2009, 57, 1192–1203. [CrossRef] [PubMed]

-Kemp, K.; Hares, K.; Mallam, E.; Heesom, K.J.; Scolding, N.; Wilkins, A. Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival. J. Neurochem. 2010, 114, 1569–1580.

-Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010 Mar 31;28(3):585-96.

-Zhang, J.; Li, Y.; Chen, Y.; Cui, Y.; Lu, M.; Elias, S.B.; Mitchell, J.B.; Hammill, L.; Vanguri, P.; Chopp, M. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol.

, 195, 16–26. [CrossRef] [PubMed]

-Gordon, D.; Pavlovska, G.; Glover, C.P.; Uney, J.B.; Wraith, D.; Scolding, N.J. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci. Lett. 2008, 448, 71–73. [CrossRef] [PubMed]

-Kassis, I.; Grigoriadis, N.; Gowda-Kurkalli, B.; Mizrachi-Kol, R.; Ben-Hur, T.;Slavin,S. ;Abramsky, O.;Karussis,D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalitis. Arch. Neurol. 2008, 65, 753–761. [CrossRef] [PubMed]

-Bonab, M.M.; Sahraian, M.A.; Aghsaie, A.; Karvigh, S.A.; Hosseinian, S.M.; Nikbin, B.; Lotfi, J.;Khorramnia, S.; Motamed, M.R.; Togha, M.; et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: An open label study. Curr. Stem Cell Res. Ther. 2012, 7, 407–414. [CrossRef] [PubMed]

-Karussis, D.; Karageorgiou, C.; Vaknin-Dembinsky, A.; Gowda-Kurkalli, B.; Gomori, J.M.; Kassis, I.;Bulte, J.W.; Petrou, P.; Ben-Hur, T.; Abramsky, O.; et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 2010, 67, 1187–1194. [CrossRef] [PubMed]

-Harris, V.K.; Vyshkina, T.; Sadiq, S.A. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Cytotherapy 2016, 18, 1476–1482. [CrossRef] [PubMed]

-Freedman, M.S.; Bar-Or, A.; Atkins, H.L.; Karussis, D.; Frassoni, F.; Lazarus, H.; Scolding, N.; Slavin, S.; Le Blanc, K.; Uccelli, A.; et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Mult. Scler. 2010, 16, 503–510. [CrossRef] [PubMed]




DOI: http://dx.doi.org/10.7575/aiac.abcmed.v.8n.1p.6

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2020 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine